Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

461 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Chemotherapy combined with immune checkpoint inhibitors may overcome the detrimental effect of high neutrophil-to-lymphocyte ratio prior to treatment in esophageal cancer patients.
Hirasawa Y, Kubota Y, Mura E, Suzuki R, Tsurui T, Iriguchi N, Ishiguro T, Ohkuma R, Shimokawa M, Ariizumi H, Horiike A, Wada S, Yamashita T, Ariyoshi T, Goto S, Otsuka K, Murakami M, Kiuchi Y, Yoshimura K, Tsunoda T. Hirasawa Y, et al. Among authors: shimokawa m. Front Oncol. 2024 Oct 11;14:1449941. doi: 10.3389/fonc.2024.1449941. eCollection 2024. Front Oncol. 2024. PMID: 39464714 Free PMC article.
Non-classical Monocytes Enhance the Efficacy of Immune Checkpoint Inhibitors on Colon Cancer in a Syngeneic Mouse Model.
Goshima T, Ieguchi K, Onishi N, Shimizu T, Takayanagi D, Watanabe M, Fujimoto Y, Ohkuma R, Suzuki R, Tsurui T, Mura E, Iriguchi N, Ishiguro T, Shimokawa M, Hirasawa Y, Kubota Y, Ariizumi H, Horiike A, Yoshimura K, Tsuji M, Kiuchi Y, Kobayashi S, Fujishiro J, Hoffman RM, Tsunoda T, Wada S. Goshima T, et al. Among authors: shimokawa m. Anticancer Res. 2024 Jan;44(1):23-29. doi: 10.21873/anticanres.16784. Anticancer Res. 2024. PMID: 38159965
Maximum Efficacy of Immune Checkpoint Inhibitors Occurs in Esophageal Cancer Patients With a Low Neutrophil-to-Lymphocyte Ratio and Good Performance Status Prior to Treatment.
Hirasawa Y, Kubota Y, Mura E, Suzuki R, Tsurui T, Iriguchi N, Ishiguro T, Ohkuma R, Shimokawa M, Ariizumi H, Horiike A, Wada S, Ariyoshi T, Goto S, Otsuka K, Murakami M, Kiuchi Y, Yoshimura K, Hoffman RM, Tsunoda T. Hirasawa Y, et al. Among authors: shimokawa m. Anticancer Res. 2024 Aug;44(8):3397-3407. doi: 10.21873/anticanres.17160. Anticancer Res. 2024. PMID: 39060084
Immune Stress-induced Tumor Mutation Burden and Neoantigen Expression in 4T1 Mammary Cancer Cells: A Potential Mechanism for Long-term Survival in Patients Treated With Immune Checkpoint Inhibitors.
Ishiguro T, Takeda K, Takayanagi D, Mura E, Suzuki R, Tsurui T, Iriguchi N, Hirasawa Y, Ohkuma R, Shimokawa M, Ariizumi H, Kubota Y, Horiike A, Izumizaki M, Wada S, Yoshimura K, Hoffman RM, Tsunoda T. Ishiguro T, et al. Among authors: shimokawa m. Cancer Genomics Proteomics. 2025 Jan-Feb;22(1):1-12. doi: 10.21873/cgp.20481. Cancer Genomics Proteomics. 2025. PMID: 39730175 Free PMC article.
A Phase II, Open Label, Single-Arm Study on the Efficacy of Cabozantinib in Patients With Advanced/Metastatic Nonsmall Cell Lung Cancer Harboring MET Exon 14 Alterations who Developed Acquired Resistance to Tepotinib or Capmatinib (CAPTURE Trial).
Takeda M, Ota M, Iwama E, Sugawara S, Shukuya T, Umemura S, Tanaka H, Oki M, Takahama T, Masuda T, Nogami N, Shimokawa M. Takeda M, et al. Among authors: shimokawa m. Clin Lung Cancer. 2024 Dec 9:S1525-7304(24)00267-5. doi: 10.1016/j.cllc.2024.12.004. Online ahead of print. Clin Lung Cancer. 2024. PMID: 39743377
Impact of the distance of spread through air spaces in non-small cell lung cancer.
Hashinokuchi A, Akamine T, Toyokawa G, Matsudo K, Nagano T, Kinoshita F, Kohno M, Tomonaga T, Kohashi K, Shimokawa M, Oda Y, Takenaka T, Yoshizumi T. Hashinokuchi A, et al. Among authors: shimokawa m. Interdiscip Cardiovasc Thorac Surg. 2024 Dec 25;40(1):ivae181. doi: 10.1093/icvts/ivae181. Interdiscip Cardiovasc Thorac Surg. 2024. PMID: 39705189 Free PMC article.
Corrigendum to 'MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC' [Journal of Thoracic Oncology 19 Issue 3 (2024) 434-450].
Haratake N, Ozawa H, Morimoto Y, Yamashita N, Daimon T, Bhattacharya A, Wang K, Nakashoji A, Isozaki H, Shimokawa M, Kikutake C, Suyama M, Hashinokuchi A, Takada K, Takenaka T, Yoshizumi T, Mitsudomi T, Hata AN, Kufe D. Haratake N, et al. Among authors: shimokawa m. J Thorac Oncol. 2024 Dec 18:S1556-0864(24)02499-7. doi: 10.1016/j.jtho.2024.12.004. Online ahead of print. J Thorac Oncol. 2024. PMID: 39692639 Free article. No abstract available.
461 results